Citigroup Maintains Neutral on Tandem Diabetes Care, Raises Price Target to $22

Benzinga · 2d ago
Citigroup analyst Joanne Wuensch maintains Tandem Diabetes Care (NASDAQ:TNDM) with a Neutral and raises the price target from $16 to $22.